The Gam-COVID-Vac vaccine was evaluated in a phase 3 trial at 25 hospitals and polyclinics in Russia .

Vaccine effectiveness against COVID-19 beyond 6 months remains incompletely understood .

COVID-19 cardiovascular

CV manifestations and sequelae of COVID-19

Also called COVID heart, coronavirus cardiovascular, long COVID cardiac

Sources: 12 new papers · 5 key papers · updated Oct 20, 2026

Overview

Unverified · drafted by AI from the sources cited below

Definition

COVID-19 is a viral disorder caused by the SARS-CoV-2 VIRUS.1 Cardiovascular diseases are pathological conditions involving the cardiovascular system, including the heart, blood vessels, or pericardium.

Diagnosis and risk stratification

Molecular tests such as PCR are highly sensitive and specific at detecting viral RNA for confirming diagnosis.1 Antigen rapid detection tests detect viral proteins and are lower cost.1

Journal clubs discussing COVID-19 cardiovascular

Recent sessions

Cardio-Oncology Journal Club – Session #1

Cardio-Oncology & Indiana University Indianapolis — Thu, Jul 9, 10:15 AM EDT

Sessions from public communities on Synapse. RSVP to join the live discussion.

Key papers

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia

The Lancet — Logunov D

1,748 citations · 2021 · among the most cited on COVID-19 cardiovascular

The Lancet women and cardiovascular disease Commission: reducing the global burden by 2030

The Lancet — Vogel B

1,586 citations · 2021 · among the most cited on COVID-19 cardiovascular

Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials

The Lancet — Ridker P

711 citations · 2023 · among the most cited on COVID-19 cardiovascular

Diagnostics for COVID-19: moving from pandemic response to control

The Lancet — Peeling R

487 citations · 2021 · among the most cited on COVID-19 cardiovascular

Risk of infection, hospitalisation, and death up to 9 months after a second dose of COVID-19 vaccine: a retrospective, total population cohort study in Sweden

The Lancet — Nordström P

339 citations · 2022 · among the most cited on COVID-19 cardiovascular

How this page is built

A clinical question appears here only when its condition matches this topic, an outcome and a comparator were extracted from the studies, at least two studies and a patient count are on file, and the certainty is low or higher.

Supports benefit, no benefit shown, and mixed describe the direction of the measured effect. No benefit shown means the evidence does not support a benefit. It is not a finding of harm. Too little evidence means the question did not clear that bar.

Study count, RCT count, and patient count are separate. The patient total adds only studies that are linked into a study family and whose sample size is not flagged as implausible. A reversal is listed only when at least one randomized trial sits on each side of the change.

The overview is drafted from the guideline recommendations, trials, papers, and questions on this page, and every sentence has to cite one of them. It stays unverified until an NPI-verified clinician or a Synapse admin approves it. Approving records that person's name.

COVID-19 cardiovascular

Overview

Definition

Diagnosis and risk stratification

Treatment

Open questions

New research on COVID-19 cardiovascular

Journal clubs discussing COVID-19 cardiovascular

Recent sessions

Key papers

How this page is built

Leading authors